IPSEN (OTCMKTS:IPSEY) Stock Passes Above 200 Day Moving Average - Should You Sell?

Key Points

• IPSEN's stock price recently crossed above its 200-day moving average of $29.57, reaching a high of $32.79 during trading, signaling potential upward momentum.
• Deutsche Bank reaffirmed a "buy" rating for IPSEN shares, suggesting confidence in the company's prospects.
• IPSEN announced an increase in its dividend, paying $0.2896 per share, which reflects a yield of 0.97%, up from the previous dividend of $0.23.

Shares of IPSEN (OTCMKTS:IPSEY - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $29.57 and traded as high as $32.79. IPSEN shares last traded at $32.42, with a volume of 391 shares.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of IPSEN in a report on Wednesday, April 2nd.

IPSEN Stock Performance

The stock has a 50-day simple moving average of $30.11 and a 200 day simple moving average of $29.57.

IPSEN Increases Dividend

The firm also recently disclosed a dividend, which was paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th were paid a dividend of $0.2896 per share. This represents a dividend yield of 0.97%. This is a boost from IPSEN's previous dividend of $0.23. The ex-dividend date was Monday, June 9th.

IPSEN Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.